Prospect News: News for Purdue Pharma LP

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with P > Issuers starting with P, DD only > All stories on Purdue Pharma LP > Stories on Purdue Pharma LP, DD only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Purdue Pharma LP

3/24/2025	DD	Purdue Pharma mediators give court sixth interim status report
3/19/2025	DD	Purdue Pharma files $7.4 billion plan, eyes May disclosures hearing
2/24/2025	DD	Purdue Pharma debtors give operating results for January
2/21/2025	DD	Purdue Pharma mediators provide terms of settlement in update
2/14/2025	DD	Purdue Pharma monitor recommends work on CVS, Rite Aid agreements
2/12/2025	DD	Purdue Pharma asks court to extend mediation through end of March
2/5/2025	DD	Purdue Pharma debtors give operating results for December
1/28/2025	DD	Purdue Pharma mediation extended through end of February
1/24/2025	DD	Purdue Pharma seeks 35-day extension of preliminary injunction
1/21/2025	DD	Purdue Pharma settlement now includes all Sackler parties: mediators
1/9/2025	DD	Purdue Pharma mediation may be subject to further extension
12/23/2024	DD	Purdue Pharma debtors see $14 million operating profit for November
12/12/2024	DD	Purdue Pharma asks court to extend mediation through Jan. 22
11/26/2024	DD	Purdue Pharma mediators say new plan expected to be filed in January
11/25/2024	DD	Purdue Pharma debtors see $25 million operating profit for October
11/12/2024	DD	Purdue Pharma plan settlement still in mediation, but progress made
11/1/2024	DD	Purdue Pharma gets more time to mediate settlement terms
10/22/2024	DD	Purdue Pharma debtors see $15 million operating profit for September
9/24/2024	DD	Purdue Pharma debtors see $9 million operating profit for August
8/23/2024	DD	Purdue Pharma debtors see $11 million operating profit for July
7/22/2024	DD	Purdue Pharma debtors see $33 million operating profit for June
7/9/2024	DD	Purdue Pharma committee seeks authority to sue Sackler family
6/27/2024	DD	Talc lawyers say Supreme Court’s Purdue decision ‘spells doom’ for J&J
6/27/2024	DD	Purdue Pharma’s plan settlement with Sacklers blocked by Supreme Court
6/25/2024	DD	Purdue Pharma debtors see $21 million operating profit for May
4/24/2024	DD	Purdue Pharma debtors see $36 million operating profit for March
9/28/2023	DD	Purdue Pharma reports $17 million operating profit for August
8/24/2023	DD	Purdue Pharma reports $10 million operating profit for July
8/10/2023	DD	Purdue Pharma’s Chapter 11 plan stayed by Supreme Court
6/28/2023	DD	Purdue Pharma reports $13 million operating profit for May
5/30/2023	DD	Purdue secures approval to sell non-opioid assets for $397 million
5/30/2023	DD	Purdue: Appeals court affirms plan confirmation, third-party releases
5/17/2023	DD	Purdue names stalking horse as winning bidder for non-opioid assets
5/1/2023	DD	Purdue Pharma gets approval of bid procedures for non-opioid assets
4/5/2023	DD	Purdue lines up $397 million stalking horse bid for non-opioid assets
2/8/2023	DD	Purdue Pharma reports $2 million operating profit for December
11/23/2022	DD	Purdue Pharma reports $5 million operating profit for October
8/24/2022	DD	Purdue Pharma reports $13 million operating profit for July, cash up
7/25/2022	DD	Purdue Pharma reports $22 million operating profit for June
6/15/2022	DD	Purdue Pharma shaves CEO’s bonus pay after pushback from states
6/10/2022	DD	Purdue Pharma unsecured creditors say CEO’s bonus should be donated
5/23/2022	DD	Purdue Pharma reports $2 million operating profit for April
5/20/2022	DD	Purdue Pharma receives court approval of 2022 employee bonus plans
5/6/2022	DD	Purdue Pharma trustee maintains concerns over key employee plans
4/28/2022	DD	Purdue Pharma submits for court approval 2022 employee bonus plans
3/11/2022	DD	Market Commentary: Endo secured notes sink in heavy secondary supply; Mallinckrodt softens; Diamond Sports mixed
3/10/2022	DD	Purdue gets approval of up to $6 billion settlement with states
3/3/2022	DD	Purdue files term sheet for up to $6 billion settlement with states
3/2/2022	DD	Purdue Pharma mediation with states, Sacklers extended indefinitely
2/22/2022	DD	Purdue Pharma mediation with states, Sacklers extended to Feb. 28
2/18/2022	DD	Purdue: Sackler family offers $1.68 billion more under settlement
2/14/2022	DD	Purdue Pharma reports $7 million operating loss for December period
2/9/2022	DD	Purdue Pharma mediation with states, Sacklers extended to Feb. 16
2/8/2022	DD	Purdue Pharma: Mediator asks for more time to conclude negotiations
2/1/2022	DD	Purdue Pharma mediation with states, Sacklers extended through Feb. 7
1/31/2022	DD	Purdue Pharma mediation could lead to additional plan funding
1/13/2022	DD	Purdue Pharma: Bankruptcy court extends mediation through Feb. 1
1/3/2022	DD	Purdue Pharma: Bankruptcy court orders mediation through mid-January
12/17/2021	DD	Purdue Pharma Chapter 11 plan confirmation overturned after appeal
12/6/2021	DD	Purdue Pharma reports $2 million operating loss for October
9/16/2021	DD	Purdue Pharma: U.S. trustee plans to appeal Chapter 11 plan confirmation
9/15/2021	DD	Purdue Pharma gets court approval of 2021 employee bonus plans
9/1/2021	DD	Purdue Pharma secures plan confirmation after three-week-long trial
8/24/2021	DD	Purdue: U.S. trustee again objects to Sackler release, attorney fees
8/6/2021	DD	Purdue Pharma reports $8 million operating loss for June period
7/27/2021	DD	Purdue Pharma says plan has ‘overwhelming support’ from creditors
7/21/2021	DD	Purdue: Examiner says Sacklers did not influence board committee
7/19/2021	DD	Purdue: U.S. trustee says Sackler release under plan is impermissible
7/12/2021	DD	Purdue Pharma: U.S. trustee objects to 2021 employee bonus plans
7/8/2021	DD	Purdue Pharma mediator says 15 states now support bankruptcy plan
6/29/2021	DD	Purdue Pharma seeks court approval of 2021 employee bonus plans
6/24/2021	DD	Purdue Pharma: Examiner appointed to investigate shareholder settlement
6/14/2021	DD	Purdue Pharma blasts creditor’s attempt to appoint examiner to case
6/3/2021	DD	Purdue Pharma gets bankruptcy court approval of disclosure statement
5/19/2021	DD	Purdue disclosure statement hearing adjourned again, now to May 26
5/14/2021	DD	Purdue Pharma Chapter 11 plan confirmation hearing set for Aug. 9
5/11/2021	DD	Purdue disclosure statement hearing adjourned again, now to May 20
4/30/2021	DD	Purdue disclosure statement hearing adjourned again, now to May 12
4/29/2021	DD	Purdue law firms to forgo $1 million in fees over failure to disclose
4/23/2021	DD	Purdue Pharma disclosure statement draws objection from West Virginia AG
4/21/2021	DD	Purdue Pharma disclosure statement lacks information, U.S. trustee says
4/19/2021	DD	Purdue Pharma sees $22 million operating profit for March period
4/12/2021	DD	Purdue Pharma disclosure statement hearing adjourned to May 4
3/16/2021	DD	Purdue files Chapter 11 plan with ‘broad and strong’ creditor support
3/1/2021	DD	Purdue gets short exclusivity extension to complete negotiations
2/16/2021	DD	Purdue seeks short exclusivity extension to complete negotiations
2/3/2021	DD	Purdue Pharma sees $22 million operating profit for December period
12/17/2020	DD	Purdue Pharma secures exclusivity extension to complete mediations
12/2/2020	DD	Purdue Pharma seeks exclusivity extension to complete mediations
11/18/2020	DD	Purdue Pharma’s $8.34 billion opioid settlement with DOJ approved
11/12/2020	DD	Purdue’s $8.34 billion opioid settlement with DOJ draws objections
10/28/2020	DD	Purdue Pharma gets approval of modified key employee incentive plan
10/21/2020	DD	Purdue Pharma reaches $8.34 billion opioid settlement with DOJ
10/2/2020	DD	Purdue Pharma debtor gets OK to sell Coventry manufacturing facility
9/22/2020	DD	Purdue Pharma: U.S. trustee objects to key employee incentive plan
9/16/2020	DD	Purdue Pharma debtor looks to sell Coventry manufacturing facility
7/27/2020	DD	Purdue Pharma receives 150-day extension of exclusive plan periods
6/26/2020	DD	Purdue Pharma OK’d to provide $6.5 million for HRT clinical trials
6/11/2020	DD	Purdue Pharma looks to provide $6.5 million for HRT clinical trials
6/4/2020	DD	Purdue Pharma: Deadline for submitting claims extended through July 30
4/30/2020	DD	Purdue Pharma marks $25 million March operating profit; sales rise
4/7/2020	DD	Purdue Pharma marks $29 million February operating profit; sales down
4/2/2020	DD	Purdue Pharma looks to pay $11.5 million to fund product development
3/5/2020	DD	Purdue Pharma: Claimant proceeds allocation issues sent to mediation
2/21/2020	DD	Purdue Pharma reports $29 million January operating profit; sales up
2/4/2020	DD	Purdue Pharma reports $9 million December operating loss; sales down
1/29/2020	DD	Purdue Pharma wins exclusivity extension to deal with ‘weighty topics’
1/13/2020	DD	Purdue Pharma eyes exclusivity extension to deal with ‘weighty topics’
12/23/2019	DD	Purdue Pharma operating profit increases to $29 million in November
11/21/2019	DD	Purdue Pharma operating profit increases to $26 million in October
10/11/2019	DD	Tribes ask Purdue Pharma court for official committee representation
10/11/2019	DD	Purdue Pharma enters injunction stipulation to allow for work on plan
9/27/2019	DD	Purdue Pharma’s nine-member unsecured creditors committee appointed
9/20/2019	BKCVDDEMHY	Prospect News reports four new defaults for week of Sept. 12-Sept. 18
9/16/2019	DD	Purdue Pharma files bankruptcy to implement opioid litigation deal

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.